Peter R. Galle
彼得·加勒
MD
Professor and Chairman, Department of Internal Medicine内科系主任及教授
👥Biography 个人简介
Peter Galle is a leading European HCC expert who has shaped ESMO clinical practice guidelines for liver cancer. He played a central role in validating atezolizumab plus bevacizumab in advanced HCC and has contributed extensively to HCC staging, surveillance, and systemic therapy trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ESMO HCC Guidelines
Served as lead author and coordinator for ESMO clinical practice guidelines on HCC, standardizing European management approaches.
Immunotherapy in HCC
Contributed to the IMbrave150 trial validating atezolizumab plus bevacizumab, transforming first-line HCC treatment globally.
HCC Surveillance and Early Detection
Advanced evidence-based frameworks for HCC surveillance in cirrhotic populations, improving early detection rates across European centers.
Representative Works 代表性著作
ESMO Clinical Practice Guidelines: Hepatocellular Carcinoma
Annals of Oncology (2021)
Definitive European guideline document integrating immunotherapy regimens into HCC management algorithms.
Atezolizumab plus bevacizumab in unresectable HCC (IMbrave150)
New England Journal of Medicine (2020)
Practice-changing trial establishing immunotherapy-based combination as new first-line standard for advanced HCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 彼得·加勒 的研究动态
Follow Peter R. Galle's research updates
留下邮箱，当我们发布与 Peter R. Galle（University Medical Center Mainz）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment